A woman who was diagnosed with stage 2 Hodgkin lymphoma has shared the symptoms that led to diagnosis, and discovering she had blood cancer. According to the NHS, Hodgkin Lymphoma is a "relatively ...

Jamie Burkitt, an associate professor of clinical small animal emergency and critical care at the University of California, Davis. Burkitt is co-chair of the Reassessment Campaign on Veterinary ...

B-ALL/NHL 2002 protocol achieved a 3-year overall survival and progression-free survival of 73% in adult patients with Burkitt lymphoma/leukemia (BL). While demonstrating efficacy comparable with ...

This latter question was a noninferiority design that aimed to preserve a similar rate of bone marrow (BM) relapse. The trial recruited children and young adults with Philadelphia-negative ALL and ...

Memo del Bosque was diagnosed with Hodgkin’s lymphoma in 2017. This aggressive cancer primarily affects white blood cells Mexican television mourns the death of Guillermo “Memo” del Bosque ...

These findings suggest this unique cell therapy approach has promise for specific patients with lymphoma, but it may be adapted for more cancer types in the future. "We observed rapid and strong ...

Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) occurs when lymphocytes called T cells and B cells become ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Advancing care for stage 3 or 4 Hodgkin lymphoma patients The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin combined with doxorubicin, vinblastine and ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...